Myriad Genetics (MYGN) Change in Acquisitions & Divestments (2009 - 2024)

Myriad Genetics (MYGN) has reported Change in Acquisitions & Divestments for 16 consecutive years, with $5.0 million the latest figure, recorded in Q3 2024.

• In Q3 2024, Change in Acquisitions & Divestments fell 66.67% year-over-year to $5.0 million; the TTM figure through Jun 2025 stood at $5.0 million (down 75.61% YoY), while the FY2024 annual figure was $9.0 million, down 91.44% from the prior year.
• Change in Acquisitions & Divestments improved to $5.0 million in Q3 2024 per MYGN's latest filing, from $2.5 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $58.1 million in Q1 2023 and bottomed at $1.5 million in Q4 2023.
• Historically, Change in Acquisitions & Divestments has averaged $23.4 million across 5 years, with a median of $20.7 million in 2020.
• Annual changes were most pronounced in 2020 — Change in Acquisitions & Divestments soared 318.9% — and 2024, when it sank 97.42%.
• Myriad Genetics' Change in Acquisitions & Divestments stood at $35.9 million in 2020, then slumped by 32.31% to $24.3 million in 2021, then soared by 67.08% to $40.6 million in 2022, then plunged by 96.31% to $1.5 million in 2023, then soared by 233.33% to $5.0 million in 2024.
• Business Quant data shows MYGN's Change in Acquisitions & Divestments at $5.0 million in Q3 2024, $2.5 million in Q2 2024, and $1.5 million in Q1 2024.